Jpmorgan Chase & CO Bluebird Bio, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BLUE
# of Institutions
158Shares Held
79.9MCall Options Held
525KPut Options Held
634K-
Black Rock Inc. New York, NY15.4MShares$7.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$4.74 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN6.39MShares$2.94 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.15MShares$2.37 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V84.67MShares$2.15 Million0.02% of portfolio
About bluebird bio, Inc.
- Ticker BLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,121,800
- Market Cap $35.5M
- Description
- bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...